Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, Campo RE, Chen SS, McColl D, Holmes CB, Enejosa J, Toole JJ CA (2008). Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. JAIDS Journal of Acquired Immune Deficiency Syndromes 47(1):74-78.
Crossref

Asiimwe SB, Kanyesigye M, Bwana B, Okello S, Muyindike W (2016). Predictors of dropout from care among HIV-infected patients initiating antiretroviral therapy at a public sector HIV treatment clinic in sub-Saharan Africa. BMC Infectious Diseases 16(1):1-10.
Crossref

Ayele T, Jarso H, Mamo G (2017). Immunological outcomes of Tenofovir versus Zidovudine based regimens among people living with HIV / AIDS : a two years retrospective cohort study. AIDS Research and Therapy 14(1)5.
Crossref

Ayele T, Jarso H, Mamo G (2017). Clinical Outcomes of Tenofovir Versus Zidovudine-based Regimens Among People Living with HIV / AIDS : a Two Years Retrospective. Open Aids Journal 11:1-11.
Crossref

Bygrave H, Ford N, Cutsem GV, Hilderbrand K, Jouquet G, Goemaere E (2011). Implementing a tenofovir-based first-line regimen in rural Lesotho, clinical outcomes and toxicities after two years. JAIDS Journal of Acquired Immune Deficiency Syndromes 56(3):e75-e78.
Crossref

Chi BH, Mwango A, Giganti MJ, Sikazwe I, Moyo C, Schuttner L (2012). Comparative outcomes of tenofovir- and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia. Journal of Acquired Immune Deficiency Syndromes 58(5):475-81.
Crossref

Costarelli S, Cozzi-lepri A, Lapadula G, Bonora S, Madeddu G, Maggiolo F, Antinori A, Galli M, Di Perri G, Viale P (2016). Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co- Administration of Other Drug Classes in Routine Clinical Practice. PloS ONE 11(10):e0160761.
Crossref

Dadi TL, Kefale AT, Mega TA, Kedir MS, Addo HA, Biru TT (2017). Efficacy and Tolerability of Tenofovir Disoproxil Fumarate Based Regimen as Compared to Zidovudine Based Regimens: A Systematic Review and Meta-Analysis. AIDS Research and Treatment 2017.
Crossref

Eguzo KN, Lawal AK, Umezurike CC, Eseigbe CE (2015). Predictors of Loss to Follow-up Among HIV-infected Patients in a Rural South-Eastern Nigeria Hospital: A 5-year Retrospective Cohort Study. Annals of Medical and Health Sciences Research 5(6):373-378.
Crossref

Ethiopian FMoH (2014). National Guidelines for Comprehensive Hiv Prevention, Care and Treatment. 

View

Federal Ministry of Health (FMOH) (2016). Health and Health Related Indicators 2008 EFY (2015/2016).

Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ (2006). Tenofovir DF Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV. New England Journal of Medicine 354(3):251-260.
Crossref

Hemasri M, Sudhapoornima P, Sowmya Sri CH, Ramya S, Avinash KKB (2016). Safety and Effectiveness of Anti-Retroviral Drug Regimens Zln and Tle in Tertiary Care Teaching Hospital : A Prospective Observational Study. Journal of Pharmacy and Biological Sciences 11(2):88-96.

Horberg M, Tang B, Towner W, Silverberg M, Bersoff-matcha S, Hurley L, Chang J, Blank J, Quesenberry Jr C, Klein D (2010). Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 53(1):62-69
Crossref

Medhanie EK, Lukman M, Massi MN, Marianti A (2015). Effectiveness of Tenofovir (TD ) / Emtricitabine (FTC) Versus Zidovudine (AZT) / Lamivudine (3TC) in Combination with Efavirenz (EFV) IN Antiretroviral-Naive HIV-Infected Patients IN Eritrea. International Journal of Pharmaceutical and Clinical Research 7:364-7.

Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, Gomis OB, Konga C, Inwoley A (2005). Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire. Antiviral Therapy 10(5):615-24.

Mudzviti T, Mudzongo NT, Gavi S, Chimbetete C (2015). A Time to Event Analysis of Adverse Drug Reactions Due to Tenofovir , Zidovudine and Stavudine in a Cohort of Patients Receiving Antiretroviral Treatment at an Outpatient Clinic in Zimbabwe. Pharmacology and Pharmacy 6(03):201.
Crossref

Njuguna C, Orrell C, Kaplan R, Bekker L, Wood R, Lawn SD (2013). Rates of Switching Antiretroviral Drugs in a Primary Care Service in South Africa before and after Introduction of Tenofovir. PLoS ONE 8(5):e63596.
Crossref

Odafe S, Torpey K, Khamofu H, Ogbanufe O, Oladele EA, Kuti O (2012). The Pattern of Attrition from an Antiretroviral Treatment Program in Nigeria. PLoS ONE 7(12):1-7.
Crossref

Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ CA (2006). Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. JAIDS Journal of Acquired Immune Deficiency Syndromes 43(5):535-540.
Crossref

Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP KN (2007). Adverse effects of highly active antiretroviral therapy in developing countries. Clinical Infectious Diseases 45(8):1093-1101.
Crossref

Tchetgen EJT, Agbaji OO, Link C, Scarsi KK, Eisen G, Darin KM (2016). Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort The Harvard community has made this article openly Tenofovir When Combined With Nevirapine-based Antiretrovi. Clinical Infectious Diseases 62:512-8.

UNAIDS (2019). UNAIDS DATA 2019. 

View

Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, Hoffmann CJ (2013). Comparison of Tenofovir , Zidovudine , or Stavudine as Part of First-Line Antiretroviral Therapy in a Resource- Limited-Setting : A Cohort Study. PLoS ONE 8(5):4-11.
Crossref

World Health Organization (WHO) (2010). Antiretroviral Therapy For HIV Infection in Adults And Adolescents; Recommendations for a public health approach -2010 revision. World Health Organization.

World Health Organization (WHO) (2013). Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV; Infection Recommendations for a Public Health Approach.

World Health Organization (WHO) (2016). Consolidated Guiedlines on The Use of Antiretroviral Drugs fro treating and preventing HIV infection: Recommendations for A Public Health Approach. 2nd ed. Genena: WHO.